Laenssjukhuset I Kalmar Region Kalmar Laen

At Laenssjukhuset I Kalmar Region Kalmar Laen, pediatric surgeons are evaluating new operative tools and diagnostic approaches to improve outcomes for children undergoing complex procedures.

• Antibiotic‑impregnated bone graft for hip arthroplasty
• Therapeutic drug monitoring of kloxacillin in S. aureus bacteremia
• Tumor treating fields combined with chemotherapy for glioblastoma
• Enhanced imaging techniques for early disease detection

The department currently supports 10 active trials led by 10 investigators, reflecting a strong commitment to innovative surgical care.

Clinical research focuses on combating resistant bacterial strains, aiming to identify safer oral regimens and infection‑preventing strategies for conditions such as Staphylococcus aureus bacteremia.

• Multidrug‑resistant urinary tract infections
• Prosthetic joint infection prevention
• S. aureus bacteremia dosing study with kloxacillin
• Extended‑spectrum beta‑lactamase urinary infections

These studies seek to reduce antibiotic resistance and improve pediatric infection management.

Trials target lymphoid malignancies, evaluating novel antibody‑based combinations to enhance remission rates in young patients with diseases like follicular lymphoma.

• Follicular lymphoma treatment with rituximab‑lenalidomide‑tafasitamab
• Mantle cell lymphoma therapy with acalabrutinib‑rituximab
• Biomarker‑driven therapy in metastatic prostate cancer

Research integrates molecular profiling to personalize therapy across hematologic cancers.

Investigations assess complement inhibition as a strategy to protect kidney function in rare immune‑mediated conditions such as C3 glomerulopathy.

• Aliskiren versus enalapril in C3 glomerulopathy
• Complement activation monitoring in renal disease
• Biomarker‑guided dosing adjustments for renal protection

Outcomes may reshape standard care for complement‑mediated kidney disease.

Research evaluates surgical adjuncts and rehabilitation methods to lower infection risk and enhance joint recovery, addressing challenges such as prosthetic joint infection.

• Antibiotic‑impregnated bone graft in hip replacement
• Post‑operative infection surveillance protocols
• Functional outcome measures after orthopedic surgery

The program aligns with the department’s focus on safe musculoskeletal interventions for children.

A broad oncology portfolio examines immunotherapy duration, combined chemoradiation, and targeted agents across several pediatric malignancies, including glioblastoma and cutaneous malignant melanoma.

• Short‑course immunotherapy for high‑risk melanoma
• TMZ/LOM versus TMZ alone in MGMT‑methylated glioblastoma
• Acalabrutinib‑rituximab in mantle cell lymphoma
• Tafasitamab addition for follicular lymphoma
• Biomarker‑driven treatment in metastatic prostate cancer

These trials aim to improve survival and reduce treatment toxicity for pediatric cancer patients.

Studies address acute neurological injuries and brain tumors, testing neuroprotective drugs and innovative radiotherapy adjuncts for conditions such as facial nerve palsy and glioblastoma.

• Cortisone therapy for acute facial nerve palsy
• Tumor treating fields with chemotherapy for glioblastoma
• Neuro‑physiological monitoring in postoperative care

Efforts focus on preserving function and enhancing quality of life for affected children.

Research includes symptom‑focused assessments, such as recovery scales after nerve injury and quality‑of‑life metrics in infection trials, exemplified by studies on facial nerve palsy.

• House‑Brackmann scale outcomes for facial palsy
• Patient‑reported outcomes in infection trials
• Biomarker‑based symptom tracking across diseases

Patient‑centered endpoints guide therapeutic decisions throughout the site’s portfolio.

Investigations explore physiological responses to surgical implants and neuro‑rehabilitation, informing device design and therapy timing for pediatric patients.

• Bone graft integration studies
• Neural plasticity after facial nerve repair
• Biomechanical analysis of joint prostheses

Findings support evidence‑based refinement of pediatric surgical practice at the Kalmar site.